Activin-ActRIIa Antagonists for Anemia and Bone Density
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for anemia, such as those using erythropoietin, are not uniformly effective, particularly in patients with cancer, end-stage renal disease, or osteoporosis, as they often result in inadequate responses and are refractory to high doses, with unclear molecular mechanisms of resistance.
Innovation Solution
The use of activin-ActRIIa antagonists, including soluble ActRIIa polypeptides and antibodies, to increase red blood cell and hemoglobin levels, which also promote bone density, offering a dual therapeutic effect for conditions like anemia and bone loss.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If erythropoietin is used to treat anemia, then red blood cell levels increase, but treatment effectiveness is insufficient in patients with cancer, end-stage renal disease, or osteoporosis
Solution Approach 1:
The patent introduces activin antagonists as intermediary substances that mediate between the administered compound and the erythropoietic system. These antagonists block activin signaling pathways, thereby enhancing the effectiveness of erythropoietin treatment across diverse patient populations including those with cancer, end-stage renal disease, and osteoporosis who previously showed inadequate responses.
Solution Approach 2:
The patent employs parameter changes by modifying the biochemical environment through activin antagonism. By altering the signaling pathway parameters (blocking activin receptors or ligands), the treatment achieves consistent erythropoietic responses across different disease states, overcoming the previously observed variability in treatment effectiveness.
2Productivity
If high doses of erythropoietin are administered, then red blood cell production is stimulated, but molecular mechanisms of resistance remain unclear and treatment remains refractory
Solution Approach 1:
Activin antagonists serve as intermediary agents that enhance erythropoietin's ability to stimulate red blood cell production. By blocking activin signaling, these intermediaries remove inhibitory effects that contribute to treatment resistance, allowing effective red blood cell production at lower erythropoietin doses and improving overall treatment responsiveness.
Solution Approach 2:
The patent applies preliminary anti-action by administering activin antagonists to preemptively block inhibitory signaling pathways before erythropoietin treatment. This preliminary blocking of activin receptors or ligands prevents resistance mechanisms from developing and enhances the subsequent erythropoietic response, making treatment more reliable across different patient populations.
3Reliability
If activin-ActRIIa antagonists are used to increase red blood cell levels, then treatment effectiveness improves, but bone density effects must be selectively managed
Solution Approach 1:
The patent applies local quality by targeting specific tissue responses differentially. Activin antagonists produce strong erythropoietic effects in the bone marrow while having minimal or selective effects on bone density. This spatial and functional differentiation allows effective anemia treatment while managing bone-related side effects through selective tissue targeting.
Solution Approach 2:
The patent utilizes parameter changes to achieve differential tissue effects. By modifying the activin signaling pathway parameters selectively, the treatment enhances red blood cell production while maintaining or selectively managing bone density parameters. This allows independent control of erythropoietic and bone metabolic parameters through the same therapeutic agent.
Data Source
AI summary
In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.